The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Mucosta     2-[(4- chlorophenyl)carbonylamino]- 3-(2-oxo...

Synonyms: Pramipide, Proamipide, Rebamipida, rebamipide, Rebamipidum, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of D01121

  • Rebamipide, a novel antiulcer agent, attenuates Helicobacter pylori induced gastric mucosal cell injury associated with neutrophil derived oxidants [1].
  • Rebamipide, a novel antiulcer agent, has been reported either to prevent various acute experimental gastric mucosal lesions or to accelerate the healing of chronic gastric ulcers [2].
  • Intraperitoneal administration of rebamipide at 60 mg/kg body weight reduced gastric mucosal hemorrhagic lesions and lipid peroxidation, which was proportional to the inhibitory effect of rebamipide on alcohol-induced xanthine oxidase-type conversion and enzyme activity [3].
  • Clinically, it is suggested that rebamipide has the potential to prevent gastric carcinogenesis by improvement of histological gastritis [4].
  • Total RNA was extracted from MKN45 cells, a human gastric cancer cell line, following HPE-stimulation with and without rebamipide for 3 h, and differences in gene expression profiles were observed using GeneChip and Human 6800 probe array [5].

Psychiatry related information on D01121


High impact information on D01121


Chemical compound and disease context of D01121


Biological context of D01121


Anatomical context of D01121

  • This change was significantly attenuated by rebamipide at a concentration less than 1 mM, showing that rebamipide may inhibit oxidant production from H pylori elicited neutrophils [1].
  • Our studies suggest that rebamipide inhibits the adhesion of H. pylori to gastric epithelial cells [14].
  • Rebamipide has many biological activities for gastric mucosa such as increasing the blood flow and biosynthesis prostaglandins and the decrease of oxygen radicals [4].
  • Taken together, this study demonstrates that rebamipide inhibits neutrophil adhesion to HUVECs by a mechanism involving inhibition of transcription-dependent surface expression of E-selectin and P-selectin in H/R-stimulated endothelial cells [18].
  • These properties of rebamipide could explain its anti-inflammatory activity with respect to the digestive mucosa and could provide protection against allergic sensitization to foreign antigens in susceptible individuals [19].

Associations of D01121 with other chemical compounds


Gene context of D01121


Analytical, diagnostic and therapeutic context of D01121


  1. Rebamipide, a novel antiulcer agent, attenuates Helicobacter pylori induced gastric mucosal cell injury associated with neutrophil derived oxidants. Suzuki, M., Miura, S., Mori, M., Kai, A., Suzuki, H., Fukumura, D., Suematsu, M., Tsuchiya, M. Gut (1994) [Pubmed]
  2. Role of rebamipide on induction of heat-shock proteins and protection against reactive oxygen metabolite-mediated cell damage in cultured gastric mucosal cells. Hahm, K.B., Park, I.S., Kim, Y.S., Kim, J.H., Cho, S.W., Lee, S.I., Youn, J.K. Free Radic. Biol. Med. (1997) [Pubmed]
  3. The effect of rebamipide on gastric xanthine oxidase activity and type conversion in ethanol-treated rats. Huh, K., Shin, U.S., Lee, S.H. Free Radic. Biol. Med. (1996) [Pubmed]
  4. Review article: clinical significance of mucosal-protective agents: acid, inflammation, carcinogenesis and rebamipide. Haruma, K., Ito, M. Aliment. Pharmacol. Ther. (2003) [Pubmed]
  5. The effect of rebamipide on Helicobacter pylori extract-mediated changes of gene expression in gastric epithelial cells. Yoshida, N., Ishikawa, T., Ichiishi, E., Yoshida, Y., Hanashiro, K., Kuchide, M., Uchiyama, K., Kokura, S., Ichikawa, H., Naito, Y., Yamamura, Y., Okanoue, T., Yoshikawa, T. Aliment. Pharmacol. Ther. (2003) [Pubmed]
  6. Inhibitory effects of rebamipide on ENNG-induced duodenal carcinogenesis in mice: a possible strategy for chemoprevention of gastrointestinal cancers. Yamane, T., Nakatani, H., Matsumoto, H., Iwata, Y., Kikuoka, N., Takahashi, T. Dig. Dis. Sci. (1998) [Pubmed]
  7. Rebamipide, an antiulcer drug, prevents DSS-induced colitis formation in rats. Kishimoto, S., Haruma, K., Tari, A., Sakurai, K., Nakano, M., Nakagawa, Y. Dig. Dis. Sci. (2000) [Pubmed]
  8. Hydroxyl radical scavenging by rebamipide and related compounds: electron paramagnetic resonance study. Naito, Y., Yoshikawa, T., Tanigawa, T., Sakurai, K., Yamasaki, K., Uchida, M., Kondo, M. Free Radic. Biol. Med. (1995) [Pubmed]
  9. Gastric Helicobacter infection inhibits development of oral tolerance to food antigens in mice. Matysiak-Budnik, T., van Niel, G., Mégraud, F., Mayo, K., Bevilacqua, C., Gaboriau-Routhiau, V., Moreau, M.C., Heyman, M. Infect. Immun. (2003) [Pubmed]
  10. Comparison of the effects of rebamipide with those of cimetidine on chronic gastritis associated with Helicobacter pylori in Mongolian gerbils. Higuchi, K., Tanigawa, T., Hamaguchi, M., Takashima, T., Sasaki, E., Shiba, M., Tominaga, K., Fujiwara, Y., Oshitani, N., Matsumoto, T., Watanabe, T., Arakawa, T. Aliment. Pharmacol. Ther. (2003) [Pubmed]
  11. Effects of rebamipide in a model of experimental diabetes and on the synthesis of transforming growth factor-beta and fibronectin, and lipid peroxidation induced by high glucose in cultured mesangial cells. Ha, H., Lee, S.H., Kim, K.H. J. Pharmacol. Exp. Ther. (1997) [Pubmed]
  12. Rebamipide ameliorates hepatic dysfunction induced by ischemia/reperfusion in rats. Lee, S.M., Kim, K.H. Eur. J. Pharmacol. (1995) [Pubmed]
  13. Protection by rebamipide against acetic acid-induced colitis in rats: relationship with its antioxidative activity. Sakurai, K., Osaka, T., Yamasaki, K. Dig. Dis. Sci. (1998) [Pubmed]
  14. Effect of rebamipide, a novel antiulcer agent, on Helicobacter pylori adhesion to gastric epithelial cells. Hayashi, S., Sugiyama, T., Amano, K., Isogai, H., Isogai, E., Aihara, M., Kikuchi, M., Asaka, M., Yokota, K., Oguma, K., Fujii, N., Hirai, Y. Antimicrob. Agents Chemother. (1998) [Pubmed]
  15. The effect of rebamipide on the expression of proinflammatory mediators and apoptosis in human neutrophils by Helicobacter pylori water-soluble surface proteins. Kim, J.S., Kim, J.M., Jung, H.C., Song, I.S. Aliment. Pharmacol. Ther. (2003) [Pubmed]
  16. Rebamipide binds to iNOS-positive cells in acetic acid-treated but not in ethanol-treated rat gastric mucosa. Nakamura, M., Akiba, Y., Matsui, H., Tsuchimoto, K., Ishii, H. Aliment. Pharmacol. Ther. (2003) [Pubmed]
  17. Preventive effect of rebamipide on gastric lesions induced by ischemia-reperfusion in the rat. Kim, C.D., Hong, K.W. J. Pharmacol. Exp. Ther. (1995) [Pubmed]
  18. Rebamipide inhibits neutrophil adhesion to hypoxia/reoxygenation-stimulated endothelial cells via nuclear factor-kappaB-dependent pathway. Kim, C.D., Kim, Y.K., Lee, S.H., Hong, K.W. J. Pharmacol. Exp. Ther. (2000) [Pubmed]
  19. Review article: rebamipide and the digestive epithelial barrier. Matysiak-Budnik, T., Heyman, M., Mégraud, F. Aliment. Pharmacol. Ther. (2003) [Pubmed]
  20. Rebamipide suppresses formyl-methionyl-leucyl-phenylalanine (fMLP)-induced superoxide production by inhibiting fMLP-receptor binding in human neutrophils. Nagano, C., Azuma, A., Ishiyama, H., Sekiguchi, K., Imagawa, K., Kikuchi, M. J. Pharmacol. Exp. Ther. (2001) [Pubmed]
  21. Rebamipide inhibits ceramide-induced interleukin-8 production in Kato III human gastric cancer cells. Masamune, A., Yoshida, M., Sakai, Y., Shimosegawa, T. J. Pharmacol. Exp. Ther. (2001) [Pubmed]
  22. COX-1 and COX-2 conversely promote and suppress ischemia-reperfusion gastric injury in mice. Hiratsuka, T., Futagami, S., Tatsuguchi, A., Suzuki, K., Shinji, Y., Kusunoki, M., Shinoki, K., Nishigaki, H., Fujimori, S., Wada, K., Miyake, K., Gudis, K., Tsukui, T., Sakamoto, C. Scand. J. Gastroenterol. (2005) [Pubmed]
  23. Involvement of cytochrome P450 in the metabolism of rebamipide by the human liver. Koyama, N., Sasabe, H., Miyamoto, G. Xenobiotica (2002) [Pubmed]
  24. Effect of rebamipide on acetic acid-induced gastric ulcer in rats: involvement of hepatocyte growth factor. Udagawa, A., Shiota, G., Ichiba, M., Murawaki, Y. Scand. J. Gastroenterol. (2003) [Pubmed]
  25. Effects of rebamipide on production of several cytokines by human peripheral blood mononuclear cells. Aihara, M., Imagawa, K., Funakoshi, Y., Ohmoto, Y., Kikuchi, M. Dig. Dis. Sci. (1998) [Pubmed]
  26. Double-blind placebo-controlled multicentre studies of rebamipide, a gastroprotective drug, in the treatment of functional dyspepsia with or without Helicobacter pylori infection. Talley, N.J., Riff, D.S., Schwartz, H., Marcuard, S.P. Aliment. Pharmacol. Ther. (2001) [Pubmed]
WikiGenes - Universities